National and Kapodistrian University of Athens
Μελέτη των απλότυπων της λεκτίνης που δεσμεύει τη μαννόζη (mannose binding lectin, MBL) στον ελληνικό πληθυσμό και σε ασθενείς με λοιμώξεις
Abstract
dc:descriptionThe human defense system comprises of two distinct types of immunity: The innate (non-specific) immunity and the acquired (adaptive) immunity. The innate immunity is characterized by several unique features: rapid onset of action, existence independently to infection, recognition based on PAMPs (pathogen associated molecular patterns), non-clonal distribution and genetically pre-determined and inherited receptor specificity. It encompasses a variety of mechanisms, including anatomic and physiologic barriers, cellular elements and humoral factors such as the mannose-binding lectin (MBL). The term lectin is an, extremely wide, functional definition, including any molecule that possesses the ability to recognize and bind carbohydrates without any enzymatic activity towards them. In many members of this family, the lectinic function is served by a specific part of their molecule which is called carbohydrate recognition domain (CRD). Mannose-binding lectin belongs to the C-type subfamily (where the term C-type denotes the calcium dependency of the group) and more specifically to the collectins, which are C-type lectins with a collagen-like domain in their structure. MBL is a molecule, oligomeric in nature. The primary polypeptide chain consists of 228 amino-acids and can be divided into four structurally and functionally distinct domains: The N-terminal, the collagen-like, the “neck” and the CRD. These chains are joined together to form the basic (trimeric) subunits. These subunits undergo further oligomerization and form the circulating molecules which may be 2-mers to 6-mers. The serum levels are measured by ELISA (Enzyme-linked immunosorbent assay), exhibit age-dependency and have been shown to variate significantly in the general population. The gene for encoding for MBL (MBL2) is located on chromosome 10 and consists of 4 exons (ex1, ex2, ex3 και ex4, sized 187, 117, 69 και 371 bp respectively) and three introns (int1, int2 και int3, sized 662, 1354 and 732 bp respectively). The 1032 bp region upstream of the 5’ UTR includes the promoter. The main site of production for MBL is the liver, although transcripts of MBL2 have been found in other tissues as well. MBL is considered to be an acute phase reactant, and several regulatory elements have been mapped in the promoter region. The MBL2 is a highly polymorphic gene. Six single nucleotide polymorphisms (SNPs), mainly, determine the circulating levels. Three are located in exon1: CD52 (allele D, CGT to TGT, arginine to cystein), CD54 (allele B, GGC to GAC, glycine to aspartic acid) and CD57 (allele C, GGA to GAA, glycine to glutamic acid). Three more are located on the promoter: -550 (H/L), -221 (Y/X) και +4 (P/Q). Due to their close proximity the 6 SNPs are in linkage disequilibrium and organized in seven haplotypes HYPA, HYPD, LXPA, LYPA, LYPB, LYQA and LYQC. HYPA, LYQA belong to “high producers ”, LYPA to “intermediate producers”, LXPA to “low producers” while HYPD, LYQC and LYPB lead to extremely low or undetectable MBL. The mutant alleles D, B and C (collectively The human defense system comprises of two distinct types of immunity: The innate (non-specific) immunity and the acquired (adaptive) immunity. The innate immunity is characterized by several unique features: rapid onset of action, existence independently to infection, recognition based on PAMPs (pathogen associated molecular patterns), non-clonal distribution and genetically pre-determined and inherited receptor specificity. It encompasses a variety of mechanisms, including anatomic and physiologic barriers, cellular elements and humoral factors such as the mannose-binding lectin (MBL). The term lectin is an, extremely wide, functional definition, including any molecule that possesses the ability to recognize and bind carbohydrates without any enzymatic activity towards them. In many members of this family, the lectinic function is served by a specific part of their molecule which is called carbohydrate recognition domain (CRD). Mannose-binding lectin belongs to the C-type subfamily (where the term C-type denotes the calcium dependency of the group) and more specifically to the collectins, which are C-type lectins with a collagen-like domain in their structure. MBL is a molecule, oligomeric in nature. The primary polypeptide chain consists of 228 amino-acids and can be divided into four structurally and functionally distinct domains: The N-terminal, the collagen-like, the “neck” and the CRD. These chains are joined together to form the basic (trimeric) subunits. These subunits undergo further oligomerization and form the circulating molecules which may be 2-mers to 6-mers. The serum levels are measured by ELISA (Enzyme-linked immunosorbent assay), exhibit age-dependency and have been shown to variate significantly in the general population. The gene for encoding for MBL (MBL2) is located on chromosome 10 and consists of 4 exons (ex1, ex2, ex3 και ex4, sized 187, 117, 69 και 371 bp respectively) and three introns (int1, int2 και int3, sized 662, 1354 and 732 bp respectively). The 1032 bp region upstream of the 5’ UTR includes the promoter. The main site of production for MBL is the liver, although transcripts of MBL2 have been found in other tissues as well. MBL is considered to be an acute phase reactant, and several regulatory elements have been mapped in the promoter region. The MBL2 is a highly polymorphic gene. Six single nucleotide polymorphisms (SNPs), mainly, determine the circulating levels. Three are located in exon1: CD52 (allele D, CGT to TGT, arginine to cystein), CD54 (allele B, GGC to GAC, glycine to aspartic acid) and CD57 (allele C, GGA to GAA, glycine to glutamic acid). Three more are located on the promoter: -550 (H/L), -221 (Y/X) και +4 (P/Q). Due to their close proximity the 6 SNPs are in linkage disequilibrium and organized in seven haplotypes HYPA, HYPD, LXPA, LYPA, LYPB, LYQA and LYQC. HYPA, LYQA belong to “high producers ”, LYPA to “intermediate producers”, LXPA to “low producers” while HYPD, LYQC and LYPB lead to extremely low or undetectable MBL. The mutant alleles D, B and C (collectivelyreferred to as O, in contrast to the wild type which is denoted with A) are found in a rather high frequency all over the globe. In Caucasians, the O alleles have a cumulative frequency of 19-25%, with B being the most common. The consequences of the 6 SNPs do not involve only the amount but also the functionality of the produced molecule. It has been shown that the product of the mutant alleles is less able to form higher order oligomers and less potent in activating the complement pathway. MBL may recognize and bind to a variety of sugars, mainly mannose (the order reflects the strength of the chemical binding): N-acetyl-d-glucosamine (GlcNAc) > D-mannose/L-fucose > N- acetyl -mannosamine > maltose > glucose. Its ability to bind to the surface of microorganisms has been extensively studied. The major action of MBL, following recognition and binding, is the activation of the lectin-dependent pathway of complement which is a third, distinct from the classical and alternative pathways, mechanism, involving three serine proteases, known as MBL-associated serine proteases (MASPs). During the last 20 years it has been shown that MBL deficiency is related to susceptibility to infections. Among the clinical conditions that have been studied is meningococcal disease and septicemia in neonates. In several patients with low levels of circulating MBL and relapsing infections has been successfully administered human recombinant MBL. This study which was conducted at the Medical Genetics Laboratory (Choremio Research Center) of the Medical School Of Athens under the supervision of Prof. Emmanuel Kanavakis. We aimed to assess the distribution of the six SNPs of MBL2 in the general Greek population (371 persons), in patients with meningococcal disease (106 patients) and in neonates with urinary tract infections (122 neonates). For the purpose of this study we developed a microarray-based method for the genotypic characterization of the 6 SNPs. Throughout the analysis we used high throughput methods, including the BioRobot M48 workstation and Biorobot 3000 (Qiagen) for the extraction of DNA and the preparation of PCR reactions respectively, the Techne TC-412 thermal cycler for the performance of PCR reactions and the NanoChip 400 platform for the genotypic analysis. The NanoChip 400 is a fully automated platform applying the principles of hybridization on a microaaray basis. The characterization of each sample is based on the selective hybridization of two labeled probes, corresponding to the two alleles of a SNP, with the DNA strand on each pad of the array. Only the perfectly complementary probes will remain bind on the target strand in temperature close to the Tm. That way when a solution containing both probes is applied on the microarray and the temperature is set at the Tm of the probes, the fluorescence signal will correspond to the “wild”, “mutant” or “both”, depending on the genotype of the SNP. The basic principles of the method are as follows: The DNA fragments of interest are multiplied with PCR. The addressing of the PCR product is done on the “one sample” - “one pad of the microarray” basis and is achieved using electric current and stabilized through a biotin-streptavidin interaction . A solution containing both probes is applied on the array at temperature close to the Tm of the probes. After a short period of time, which allows the hybridization to take place, the solution is washed out, the temperature is lowered and the signal of each pad is measured. All probes for the 6 SNPs of MBL2 were designed according to the manufacturer’s instructions and guidelines. The hybridization was successful for all SNPs, with the exception of the +4 position in the meningitis and neonate population where a malfunction of the cartridge did not allow the measurement of the fluorescence sign. In the general Greek population the results were as follows: -550: H: 258/728 alleles (35.4%, 95% c.i.:32.0-39.0), L: 470/728 alleles (64.6%, 95% c.i.:61.0-68.0). -221: Y: 558/690 alleles (80.9%, 95% c.i.:77.7-83.7), X: 132/690 alleles (19.1%, 95% c.i.:16.3-22.3). +4: P: 526/690 alleles (76.2%, 95% c.i.:72.9-79.4), Q: 164/690 alleles (23.8%, 95% c.i.:20.6-27.1). CD52: A: 657/704 alleles (93.3%, 95% c.i.:91.2-95.0), D: 47/704 alleles (6.7%, 95% c.i.:4.9-8.8). CD54: A: 584/704 alleles (83.0%, 95% c.i.:80.0-85.6), B: 120/704 alleles (17.0%, 95% c.i.:14.3-20.0). CD52: A: 700/704 alleles (99.4%, 95% c.i.:98.6-99.8), C: 4/704 alleles (0.6%, 95% c.i.:0.2-1.4). The observed frequencies for SNPs -550 και -221 differed from the expected according to the Hardy-Weinberg equilibrium (p<0.05). The probability of a O/O genotype in the Greek population was 5.7% (95% c.i. 2.6-7.8%). In patients with meningococcal disease the frequency of every single SNP was comparable to the general population. The probability of a O/O genotype among patients with meningococcal disease was 7.5% (95% c.i. 2.6-7.8%) which is 1.5 times higher compared to the general population, although the result was not statistically significant (p=0.39). The distribution of the 6 SNPs of the MBL2 between neonates with urinary tract infection and the Greek population were similar. The probability of a neonate to carry two mutant alleles was 2.7% (95% c.i. 2.8-15.6%). In conclusion, in this study, a novel, microarray-based methodology was applied to characterize the 6 SNPs of the MBL2 on a large number of samples. The described technique is fast, cost-effective, reduces the probability of error and can be used for large scale studies. The observed frequencies of the 6 SNPs of the MBL2 in the Greek population are similar to those reported in the literature for Caucasians. No relation between the 6 SNPs of the MBL2 and meingococcal disease or urinary tract infection in neonates was found.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2011
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Chouliaras, Georgios
- Χουλιάρας, Γεώργιος
Subjects
dc:subject × 20- Απλότυποι
- Πληθυσμιακή μελέτη
- Πολυμορφισμοί
- Μηνιγγιτιδοκοκκική νόσος
- Ουρολοίμωξη
- Νεογνά
- Γενικός ελληνικός πληθυσμός
- Mannose binding lectin
- MBL
- MBL2
- Haplotypes
- Microarrays
- Population study
- Meningococcal disease
- Urinary tract infections
- Single nucleotide polymorhisms
- Ιατρική και Επιστήμες Υγείας
- Ιατρική Βιοτεχνολογία
- Medical and Health Sciences
- Medical Biotechnology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/27929